ELVN - NASDAQ

Enliven Therapeutics, Inc.

ELVN·NASDAQ

$37.48

+4.0%

HealthcareBiotechnology

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.28B

EPS-1.8300

P/E Ratio-20.48

Earnings Date08/12/2026

476.17M

Assets

46%

3Y+472.0%

5Y+424.0%

10Y+4558.0%

16.68M

Total Liabilities

3Y-90.0%

5Y+160.0%

10Y+1022.0%

459.60M

Total Equity

48%

3Y-698.0%

5Y+444.0%

10Y-3059.0%

Enliven Therapeutics, Inc. Funding & Solvency Profile

ELVN · NASDAQ

Current Assets

Cash & Cash Equivalents98.90M

Net Receivables0.00

Inventory0.00

Other Current Assets12.26M

Total Current Assets475 M

Non-Current Assets

Property, Plant & Equipment417.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets873.00K

Total Non-Current Assets1 M

Total Assets

476.17M

Financial Health Analysis

Current Ratio

28.66x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.04x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

458 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Enliven Therapeutics, Inc. Balance Sheet

ELVN • NASDAQ

Enliven Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	98.9M	124.1M	100.1M	75.5M	110M	47.7M	4.9M	7.4M	9.7M
Short-Term Investments	363.7M	189.3M	153M	0.0	0.0	40.5M	24M	0.0	0.0
Cash & Short-Term Investments	462.6M	313.4M	253.1M	75.5M	110M	88.2M	28.9M	7.4M	9.7M
Prepaids	0.0	0.0	2.9M	0.0	646K	0.0	0.0	0.0	0.0
Other Current Assets	12.3M	4.7M	10.1M	2.2M	0.0	2.2M	1.7M	323K	552K
Total Current Assets	474.9M	318.1M	266.2M	77.8M	110.7M	90.4M	30.6M	7.7M	10.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	417K	458K	1.1M	1.5M	954K	349K	442K	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	54K	0.0	0.0	88K	0.0	0.0
Other Non-Current Assets	873K	7.2M	4.7M	4M	1.7M	88K	2.1M	0.0	0.0
Total Non-Current Assets	1.3M	7.6M	5.7M	5.5M	2.7M	437K	2.7M	0.0	0.0
Total Assets	476.2M	325.8M	271.9M	83.3M	113.3M	90.8M	33.3M	7.7M	10.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.2M	1.3M	532K	3.4M	2.5M	2M	1.7M	908K	431K
Accounts Payable	2.2M	1.3M	532K	3.4M	2.5M	2M	1.7M	908K	431K
Accrued Expenses	0.0	14.4M	14.7M	127K	2.8M	1.1M	802K	137K	199K
Short Term Debt	399K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	335K	323K	159K	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	5.5M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	14M	204K	10.4M	320K	233K	3.2M	1.7M	787K	196K
Total Current Liabilities	16.6M	15.9M	25.9M	9.7M	5.8M	6.2M	4.2M	1.8M	826K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	660K
Deferred Tax Liabilities (Non-Current)	108K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	67K	150.4M	714K	160K	184K	32.2M	0.0
Total Non-Current Liabilities	108K	0.0	67K	150.4M	714K	160K	184K	32.2M	660K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-32.2M	0.0
Capital Lease Obligations	0.0	0.0	335K	323K	159K	0.0	0.0	0.0	0.0
Total Liabilities	16.7M	15.9M	26M	160.1M	6.5M	6.4M	4.4M	1.8M	1.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	149.7K	149.7M	0.0	0.0	0.0	0.0
Common Stock	59K	49K	41K	1K	1K	18K	4K	4K	4K
Additional Paid-In Capital	806.4M	553.2M	400.2M	6M	2.3M	180.5M	0.0	0.0	0.0
Retained Earnings	-347.2M	-243.5M	-154.4M	-82.9M	-45.2M	-96.1M	-54.8M	-31.3M	-20M
Accumulated Other Comprehensive Income/Loss	334K	55K	141K	-149.7K	0.0	4K	32K	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	5.9M	5M	4.4M
Total Stockholders' Equity	459.6M	309.8M	245.9M	-76.8M	106.9M	84.4M	-48.8M	-26.3M	-15.5M
Total Equity	459.6M	309.8M	245.9M	-76.8M	106.9M	84.4M	28.9M	-26.3M	-15.5M
SUMMARY
Total Liabilities & Equity	476.2M	325.8M	271.9M	83.3M	113.3M	90.8M	33.3M	7.7M	10.2M
Total Investments	363.7M	189.3M	153M	54K	0.0	40.5M	24.1M	0.0	0.0
Total Debt	399K	0.0	335K	323K	159K	0.0	0.0	0.0	660K
Net Debt	-98.5M	-124.1M	-99.8M	-75.2M	-109.9M	-47.7M	-4.9M	-7.4M	-9M
Shares Outstanding	59,235,547	59,235,547	59,235,547	59,235,547	59,235,547	59,235,547	59,235,547	59,235,547	59,235,547

SEC Filings

ELVN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 27, 2026	June 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 06, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 11, 2025	December 09, 2025	2025	View Filing
8-K/A 8-K/A 2025 (Amended) N/A	November 13, 2025	November 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 95 filings

Related Guides

Blog Categories

Continue your ELVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.